One preclinical study reported the efficacy of dinaciclib, a cyclin-dependent kinase (CDK) inhibitor, which showed RALB-dependent anti-leukemic activity in AML models—including patient-derived mouse xenografts—with trivial effects on non-malignant hematological progenitor cells [142]. Here, RALB is linked to acute myeloid leukemia.